Recent Updates
Recently added Catalysts
ONC Positive Sentiment

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

Friday, October 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BeOne Medicines announced positive results from the Phase 3 HERIZON-GEA-01 trial. The second interim analysis confirmed that the combination of TEVIMBRA and ZIIHERA with chemotherapy provides a sustained survival benefit for patients with HER2-positive gastroesophageal cancer. This finding supports the use of this therapy as a first-line treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • Sustained survival benefit reported
  • Combination therapy shows effectiveness
  • Positive results from Phase 3 trial

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+45%
120-day peak, hindsight
Typical move
3.5%
average across 7 past catalysts
Lead asset
BGB-43395
Phase 1 · Advanced Solid Tumor

Full Press Release Details

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GE

Frequently Asked Questions

What is the HERIZON-GEA-01 trial?

It is a Phase 3 trial evaluating TEVIMBRA and ZIIHERA in cancer treatment.

What does TEVIMBRA treat?

TEVIMBRA is used for HER2-positive gastroesophageal adenocarcinoma.

What were the results of the interim analysis?

The analysis confirmed a sustained survival benefit from the treatment.

Who conducted the HERIZON-GEA-01 trial?

The trial was conducted by BeOne Medicines Ltd.

ShareAdd on Google
Tags: ONC BeOne Medicines TEVIMBRA ZIIHERA HER2-positive oncology
Last updated: Oct 23, 2026

Biotech snapshot

Cash runway
$5098M liquidity · $0M/mo burn
Low dilution risk
Lead asset
BGB-43395Phase 1
Advanced Solid Tumor →

Catalyst track record

+45%
best trade around ONC's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ONC.

See every catalyst's timing & PoA →